



PTO FORM-1449

**INFORMATION
DISCLOSURE
CITATION**

Inventor: FRENKEL, Niza

Appl. No.: 10/567,064

Intl. Appl. No: PCT/IL04/00719

Filing Date: February 3, 2006

Intl. Filing Date: August 4, 2004

U.S. PATENT DOCUMENTS

Exam. Initial		Document No.	Issue/Public. Date	Inventor	Filed Date
	A1	6,503,752	07 Jan 2003	Frenkel	09 Nov 1994
	A2	5,194,601	16 Mar 1993	Sugden et al.	18 Sep 1989
	A3	6,544,780	08 Apr 2003	Wang	02 Jun 2000
	A4	5,230,997	27 Jul 1993	Frenkel	19 Jul 1990
	A5				
	A6				
	A7				

FOREIGN PATENT DOCUMENTS

Exam. Initial		Document No.	Public. Date	Country	Translation
	A8	WO 02/056828	25 Jul 2002	WO	N/A
	A9	WO 99/07869	08 Feb 1999	WO	N/A
	A10				
	A11				

OTHER

Exam. Initial		
	A12	Ablashi et al., "Genomic polymorphism, growth properties, and immunologic variations in human herpesvirus-6 isolates." <u>Virology</u> , v.184:545-552, 1991.
	A13	Borenstein et al., "Use of an amplicon-6 vector derived from Human Herpesvirus 6 for efficient expression of membrane-associated and secreted proteins in T cells." <u>J. Virol.</u> , v.78:4730-4743, 2004.
	A14	Engels et al., "Retroviral vectors for high-level transgene expression in T lymphocytes." <u>Hum. Gene Ther.</u> , v.14:1155-1168, 2003.
	A15	Frenkel and Hoffman, <u>Virology</u> . 3 rd Edition: Lippincott, Raven Press, pp.2609-2633 (1996).
	A16	Frenkel et al., "Isolation of a new herpesvirus from human CD4+ T cells." <u>Proc. Natl. Acad. Sci. USA</u> , v.87:748-752, 1990.
	A17	Frenkel et al., "Bone marrow transplant recipients harbor the B variant of human herpesvirus 6." <u>Bone Marrow Transplant</u> , v.14:839-843, 1994.
	A18	Frenkel et al., "The herpes simplex virus amplicon - a versatile defective virus vector." <u>Gene Therapy</u> , v.1:540-546, 1994
	A19	Hanke et al., "Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine." <u>J. Gen. Virol.</u> , v.84:361-368, 2003.
	A20	Meeker et al., "Adenoviral vectors efficiently target cell lines derived from selected lymphocytic malignancies including anaplastic large cell lymphoma and Hodgkin's disease." <u>Clin. Cancer Res.</u> , v.3:357-364, 1997.
	A21	Katsafanas et al., "In vitro activation of human herpesviruses 6 and 7 from latency." <u>Proc. Natl. Acad. Sci. USA</u> , v.93:9788-9792, 1996.

Page 2 of 2

MAIL STOP - PCT
Docket No. 27225U

PTO FORM-1449 INFORMATION DISCLOSURE CITATION		Inventor: FRENKEL, Niza	
		Appl. No.: 10/567,064	Intl. Appl. No: PCT/IL04/00719
		Filing Date: February 3, 2006	Intl. Filing Date: August 4, 2004
OTHER (CONT.)			
Exam. Initial			
	A22	Taylor-Papadimitriou et al., "MUC1 and cancer." <u>Biochem. Biophys. Acta.</u> , 1455(2-3):301-313, 1999.	
	A23	D. Pellet, "Human herpesviruses 6A, 6B, and 7 and their replication." <u>Virology</u> , v.2(80):2769-2784, 2002.	
	A24	Rapaport et al., "Antiviral prophylaxis may prevent human herpesvirus-6 reactivation in bone marrow transplant recipients." <u>Transpl. Infec. Dis.</u> , v.4:10-16, 2002.	
	A25	Romi et al., "Tamplicon-7, a novel T-lymphotropic vector derived from human herpesvirus 7." <u>J. Virol.</u> , v.73:7001-7007, 1999.	
	A26	Schirmer et al., "Differentiation between two distinct classes of viruses now classified as human herpes virus 6." <u>Proc. Natl. Acad. Sci. USA</u> , v.88:199-208, 1991.	
	A27	Wyatt and Frenkel, "Human herpes virus 7 is a constitutive inhabitant of adult human saliva." <u>J. Virol.</u> , v.66:3206-3209, 1992.	
	A28	K. Yamanishi, "Human herpesvirus 6." <u>Microbiol. Immunol.</u> , v.36:551-561, 1992.	
Examiner		Date Considered	
/David Montanari/		10/14/2009	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP'609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			